Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celtic Pharmaceutical Holdings L.P.

http://www.celticpharmaholdings.com/

Latest From Celtic Pharmaceutical Holdings L.P.

Finance Watch: PTC Secures Up To $1bn In Funding From Blackstone

Public Company Edition: PTC will get $350m up front as part of an initial $500m commitment. Also, while Biohaven and Vaxcyte launched traditional follow-on offerings, Recursion and Agios took the private placement and royalty sale routes, while others revealed job cuts and other strategic updates. 

Financing Business Strategies

Behind The First Inhaled COVID Vaccine: Chinese-Language CEO Podcast With CanSino’s Xuefeng Yu

After securing the first approval globally for an inhaled COVID-19 vaccine, Chinese biotech CanSino CEO Xuefeng Yu sat down with Scrip in this Chinese-language interview to share his views on vaccine development and market opportunities in China and elsewhere.

China Business Strategies

Servier’s Kamoun On Breaking Brain Cancer Barriers By Harnessing Cancer Metabolism

The private French firm’s new global head of R&D oncology spoke with Scrip about its two-pronged oncology strategy and its high hopes for the advanced glioma candidate, vorasidenib, which may improve upon Tibsovo.

Companies Cancer

Finance Watch: 3T Biosciences Emerges With $40m And Novel TCR Platform

Private Company Edition: Westlake Village BioPartners’ latest launch 3T Biosciences also licensed a second TCR platform from Stanford University. In other recent financings, Senda raised a $123m series C round, Orna revealed a $221m series B and CPRIT funded several cancer drug developers.

Financing Innovation
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
    • Drug Delivery
      • Transdermal
  • Other Names / Subsidiaries
    • Auven Therapeutics Management L.L.L.P.
    • Celtic Pharma Management
    • Xenova Limited
    • Celtic Therapeutics Holdings L.P.
UsernamePublicRestriction

Register